One year on, Capri­cor's stem cell ther­a­py ap­pears to help DMD pa­tients in small study, but in­vestors balk at the da­ta

Re­peat­ed set­backs aside, lit­tle Capri­cor has sug­gest­ed it has gen­er­at­ed some long-term da­ta to sup­port its pur­suit to gar­ner ap­proval for its stem cell ther­a­py for Duchenne mus­cu­lar dy­s­tro­phy, al­though some of the da­ta ap­peared to un­der­whelmed in­vestors.

The da­ta from the small, place­bo-con­trolled mid-stage study, HOPE-2, tracked the ef­fects of the com­pa­ny’s stem cell ther­a­py CAP-1002, which is de­signed to tem­per the in­flam­ma­tion as­so­ci­at­ed with DMD, in 8 boys and young men who are in ad­vanced stages of DMD. The re­main­ing 12 en­rolled pa­tients re­ceived the place­bo.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.